Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. Juli 2021 16:01 ET | Quelle: NeoTX

NeoTX Hosting Key Opinion Leader Webinar on Overcoming Check Point Inhibitor Resistance

REHOVOT, Israel, July 07, 2021 (GLOBE NEWSWIRE) -- NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced today that it will host a key opinion leader (KOL) webinar on...
19. April 2021 02:30 ET | Quelle: NeoTX

NeoTX Announces FDA Clearance of IND for Phase 2 Clinical Trial of Naptumomab Estafenatox (NAP), its lead Tumor Targeted Superantigen Candidate

REHOVOT, Israel, April 19, 2021 (GLOBE NEWSWIRE) -- NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced today that it received clearance from the U.S. Food and Drug...
03. August 2020 08:00 ET | Quelle: NeoTX

NeoTX to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium

REHOVOT, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- NeoTX Therapeutics, a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection (STR) platform to develop...
19. Februar 2020 03:00 ET | Quelle: NeoTX

NeoTX Closes $45 Million Series C Financing

REHOVOT, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- NeoTX Therapeutics, a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection (STR) platform to develop...
04. November 2019 08:00 ET | Quelle: NeoTX

NeoTX Therapeutics to Present at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

REHOVOT, Israel, Nov. 04, 2019 (GLOBE NEWSWIRE) -- NeoTX Therapeutics, Ltd. today announced a presentation on the company’s lead candidate from its Selective T cell Redirection (STR) platform,...
28. Oktober 2019 03:30 ET | Quelle: NeoTX

NeoTX Announces First Patient Dosed in Phase 1b Trial of Naptumomab Estafenatox (Nap) in Combination with Durvalumab in Solid Tumors

Dose-escalation study to determine maximum tolerated dose ahead of Phase 2 cohort expansion study Milestone marks initiation of studies in the NeoTX-AstraZeneca collaboration to study Nap in...